20 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Gainers

• Curis, Inc. CRIS shares increased by 61.48% to $1.97 during Wednesday's pre-market session.

• Plus Therapeutics, Inc. PSTV shares rose 18.45% to $2.76.

• Alterity Therapeutics, Inc. ATHE shares increased by 16.80% to $0.73.

• InVivo Therapeutics Hldg, Inc. NVIV shares increased by 15.46% to $2.39.

• Capricor Therapeutics, Inc. CAPR shares moved upwards by 12.02% to $5.22.

• Tetraphase Pharmaceutical, Inc. TTPH shares increased by 10.41% to $2.44. According to the most recent rating by Gabelli & Co., on Mar 17, the current rating is at Sell.

• Sunesis Pharmaceuticals, Inc. SNSS shares increased by 9.42% to $0.53. The most recent rating by H.C. Wainwright, on May 8, is at Neutral, with a price target of $0.

• Allied Healthcare Prods, Inc. AHPI stock moved upwards by 9.03% to $8.81.

• Check-Cap, Inc. CHEK stock moved upwards by 8.71% to $0.75. The most recent rating by H.C. Wainwright, on Apr 24, is at Buy, with a price target of $2.

• Vermillion, Inc. VRML stock increased by 8.46% to $4.87.

Losers

• Immuron, Inc. IMRN stock decreased by 32.65% to $13.47 during Wednesday's pre-market session.

• Cardiovascular Systems, Inc. CSII stock declined 11.36% to $34.02. The most recent rating by SVB Leerink, on Apr 28, is at Outperform, with a price target of $50.

• Quidel, Inc. QDEL shares fell 6.93% to $145.01. The most recent rating by JP Morgan, on May 12, is at Underweight, with a price target of $158.

• Aptevo Therapeutics, Inc. APVO stock fell 6.83% to $6.

• Aethlon Medical, Inc. AEMD shares fell 6.54% to $1.43.

• Second Sight Medical, Inc. EYES shares decreased by 5.84% to $1.45.

• Precipio, Inc. PRPO stock fell 4.55% to $1.05.

• DBV Technologies, Inc. DBVT stock declined 4.55% to $5.66. The most recent rating by Citigroup, on Apr 6, is at Buy, with a price target of $10.

• Cidara Therapeutics, Inc. CDTX shares fell 4.11% to $3.50.

• Ascendis Pharma, Inc. ASND stock fell 3.98% to $136. The most recent rating by Morgan Stanley, on May 21, is at Overweight, with a price target of $181.